Comparison of 3 dosing regimens of Advagraf to determine if there is a dosing regimen which may have the potential to cause fewer kidney problems.

• Drug: Advagraf
  Capsule
  Other Names:

  • FK506E
  • MR4
  • tacrolimus modified release
• Drug: Mycophenolate Mofetil
  Solution for infusion
  Other Name: MMF
• Drug: Basiliximab
  IV infusion
  Other Name: Simulect
• Drug: Corticosteroids
  IV bolus
  Other Name: Methylprednisolone or equivalent

• Dosing Regimen 1: Experimental
  Advagraf + MMF + Corticosteroids (Bolus)
  Interventions:

  • Drug: Advagraf
  • Drug: Mycophenolate Mofetil
  • Drug: Corticosteroids
• Dosing Regimen 2: Experimental
  Advagraf + MMF + Basiliximab + Corticosteroids (Bolus)
  Interventions:

  • Drug: Advagraf
  • Drug: Mycophenolate Mofetil
  • Drug: Basiliximab
  • Drug: Corticosteroids
• Dosing Regimen 3: Experimental
  Advagraf (5 days delay) + MMF + Basiliximab + Corticosteroids (Bolus)
  Interventions:

  • Drug: Advagraf
  • Drug: Mycophenolate Mofetil
  • Drug: Basiliximab
  • Drug: Corticosteroids

Inclusion Criteria:

• Undergoing orthotopic liver or split liver allograft transplantation
• Female subject of childbearing potential must have a negative serum or urine pregnancy test at enrollment and must agree to maintain effective birth control during the study

Exclusion Criteria:

• Receiving a multi-organ transplant or having previous received an organ transplant (including liver re-transplantation)
• Receiving an auxiliary graft or in whom a bio-artificial liver (cell system) has been used
• Receiving ABO incompatible graft or a graft from a non heart beating donor
• Ongoing dosing with systemic corticosteroids
• Subjects with systemic infection requiring treatment except viral hepatitis

• Diagnosis of new-onset malignancy prior to transplantation, with the exception of basocellular or squamous cell carcinoma of the skin which had been treated successfully. However, subjects with primary liver carcinoma can be included if they meet the following criteria:

  • < 3 nodes
  • no node larger than 5 cm
  • no metastases
  • no vascular tumoral invasion
• Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer
• Subject or donor known to be HIV positive
• Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, basiliximab or mycophenolate mofetil or any of the product excipients
• Pregnant woman or breast-feeding mother
• Currently participating in another clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment
• Unlikely to comply with the Visits scheduled in the protocol
• Any unstable medical condition that could interfere with the study objectives in the opinion of the Investigator
• Receiving prohibited concomitant therapy, or received prohibited concomitant therapy within 28 days prior to enrollment
• Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the Investigator, may complicate communication with the Investigator